How Dartmouth Geisel School of Medicine and Quanterix Accelerated NLRP3 Detection

Developing novel biomarker assays for neurodegenerative research can be complex, time-intensive, and require deep expertise. In collaboration with the Geisel School of Medicine at Dartmouth and the Michael J. Fox Foundation, the Quanterix Accelerator Lab helped develop a high-sensitivity Simoa® assay to measure NLRP3 inflammasome levels—a key marker of neuroinflammation in Parkinson’s disease.

Watch this short video highlighting the collaboration and its impact on biomarker research:

In this case study, learn how:

• Dr. Matthew Havrda’s research team overcame assay sensitivity challenges
• Simoa technology enabled the detection of NLRP3 in previously undetectable samples
• Custom assay development accelerated biomarker translation for clinical research

Download the full case study to explore how Simoa ultra-sensitive biomarker detection and custom assay development are advancing neurodegenerative research.